CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Summary

This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications